High Efficiency Dialyzer Development

本项目的目标是开发一种高效的活性混合料 肾功能衰竭患者使用的血液透析器。我们打算复制我们的 当前的主动混合膜式氧合器(AMMO)技术 正在开发中的这种设备。弹药装置中的传质有 事实证明，其效率是目前可用的静态性能的5-8倍 氧合器，同时不会造成比这些临床上更多的血液损害 设备。此外，弹药的旋转运动导致了 它是一个非常高效的泵，因此包含了两个基本的 在单个设备中运行。 主动混合功能，通过传授间隙来提高效率 中空纤维阵列内的对流和减少血相 阻力，从而提高传质效率。在其他 换句话说，纤维束的运动破坏了浓度边界。 阻碍跨膜传质的层。 此第一阶段计划旨在评估我们的 设计。具体地说，使用为 我们将制造多个有源混合透析器原型 合适的透析微孔纤维和透析液的变化 流畅的通道。这些单位随后将根据美国急性心肌梗死进行体外评估。 标准。根据获得的净空数据，我们将选择 高效透析器，并制造一套相同的单元，以便进一步 功能评估。最后，对三项体外动物试验进行基本评估 提出了活性混合型透析器的生物相容性。 建议的商业应用： 超过20万美国人需要血液透析。主动者 混合血液透析器有可能提供更有效的， 因此更少的时间和更低的生物材料暴露， 血液透析治疗。此外，该设备还将泵送血液 从而消除了当前系统的另一个元素。会是 可集成到今天的透析机中，从而消除了 用于昂贵的资本支出。

The goal of this project is develop a highly efficient active mixing hemodialyzer for patients in renal failure. We intend to replicate our active mixing membrane oxygenator (AMMO) technology currently under development to this device. Mass transfer in AMMO devices has proven to be 5-8 times more efficient than currently available static oxygenators, while not causing more blood damage than these clinical devices. In addition, the rotational movement of AMMO has resulted in it being a very efficient pump, thereby incorporating two basic functions in a single device. Active mixing functions to increase efficiency by imparting interstitial convection within the hollow fiber array and reducing blood phase resistance, resulting in increased mass transfer efficiency. In other words, motion of the fiber bundle disrupts the concentration boundry layer that impedes mass transfer across the membrane. This Phase I program is designed to evaluate the feasibility of our design. Specifically, using fabrication techniques developed for AMMO we will fabricate multiple active mixing dialyzer prototype variations with appropriate dialysis microporous fibers and dialysate fluid pathways. These units will then be evaluated in vitro per AAMI standards. Based on clearance data obtained we will select the most efficient dialyzer and fabricate a set of identical units for further functional evaluation. Finally, three ex-vivo animal trials to assess basic biocompatibility of the active mixing dialyzer are proposed. PROPOSED COMMERCIAL APPLICATION: Hemodialysis is required by over 200,000 Americans. The active mixing hemodialyzer has the potential to provide for more efficient, hence less time-consuming and lower biomaterials exposure, hemodialysis treatments. In addition, this device will pump blood thereby eliminating another element of current systems. It will be integratable into today's dialysis machines thereby eliminating the need for costly capital expenditures.